Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018)
Anaptysbio's (ANAB) quarterly Non-Current Deffered Revenue came in at $171000.0 in Q4 2018, up 22.14% YoY from $140000.0 in Q4 2017, and up 5.56% on a QoQ basis from $162000.0 in Q3 2018.
Powered by 
Analysis
Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018) Analysis & Trends
Anaptysbio (ANAB) has 3 years of Non-Current Deffered Revenue data on file, last reported at $171000.0 in Q4 2018.
- Quarterly Non-Current Deffered Revenue rose 22.14% year-over-year to $171000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $171000.0 (up 22.14% YoY) and the FY2018 annual result came in at $171000.0, up 22.14% from the prior year.
- Non-Current Deffered Revenue grew to $171000.0 in Q4 2018, from $162000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $171000.0 in Q4 2018 to a low of $128000.0 in Q2 2018.
- A 3-year average of $151555.6 and a median of $154000.0 in 2016 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 22.14% in 2018, down 23.81% in 2018.
- Tracing ANAB's Non-Current Deffered Revenue over 3 years: stood at $154000.0 in 2016, then dropped by 9.09% to $140000.0 in 2017, then gained by 22.14% to $171000.0 in 2018.
- The last three Non-Current Deffered Revenue figures came in at $171000.0 (Q4 2018), $162000.0 (Q3 2018), and $128000.0 (Q2 2018), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 171,000.00 |
| Sep 30, 2018 | 162,000.00 |
| Jun 30, 2018 | 128,000.00 |
| Mar 31, 2018 | 133,000.00 |
| Dec 31, 2017 | 140,000.00 |
| Sep 30, 2017 | 147,000.00 |
| Jun 30, 2017 | 168,000.00 |
| Mar 31, 2017 | 161,000.00 |
| Dec 31, 2016 | 154,000.00 |